Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Diphenhydramine vs ACTIFED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Allergic rhinitis,Urticaria,Pruritus,Insomnia (OTC sleep aid),Motion sickness,Parkinsonism (off-label for extrapyramidal symptoms)
Temporary relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, pruritus),Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
Terminal elimination half-life 4-8 hours in adults; prolonged in hepatic impairment (up to 20 hours) and elderly.
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (p H-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2C9, and CYP2C19; undergoes N-demethylation and N-oxidation; first-pass metabolism is extensive.
Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%).
Primarily renal (90-95% as metabolites, <5% unchanged). Minor biliary/fecal elimination (<5%).
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
98-99% bound, primarily to albumin.
Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin).
Vd 3-5 L/kg (wide distribution, high tissue binding).
Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution.
Oral: 50-70% (first-pass metabolism). IM: 100% (assumed). IV: 100%.
Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible).
No specific dose adjustment for GFR. Use with caution in severe renal impairment (Cr Cl <10 m L/min) due to potential accumulation; consider reducing dose or extending interval.
Cr Cl 30-50 m L/min: extend dosing interval to every 8 hours. Cr Cl 15-29 m L/min: every 12 hours. Cr Cl <15 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider 25% of usual dose or avoid.
Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use.
Children 2-5 years: 6.25 mg orally every 4-6 hours (max 37.5 mg/day). Children 6-11 years: 12.5-25 mg orally every 4-6 hours (max 150 mg/day). Children ≥12 years: 25-50 mg orally every 4-6 hours (max 300 mg/day).
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended.
Elderly patients (>65 years): initially 25 mg orally at bedtime, increase if needed; maximum 50 mg/day. Avoid as first-line antihistamine due to anticholinergic adverse effects (confusion, falls).
Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects.
Not recommended for use in neonates or premature infants due to potential association with sudden infant death syndrome (SIDS) and paradoxical CNS excitation.
None.
Causes significant sedation, impairing ability to drive or operate machinery; anticholinergic effects may exacerbate narrow-angle glaucoma, urinary retention, hyperthyroidism, hypertension, and prostatic hypertrophy; avoid concurrent use with alcohol or other CNS depressants.
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias,CNS stimulation: nervousness, dizziness, insomnia, especially in elderly,May cause urinary retention in patients with prostatic hypertrophy,Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure,Anticholinergic effects: dry mouth, blurred vision, constipation
Hypersensitivity to diphenhydramine or any antihistamine; acute asthma attack; concurrent MAOI therapy; breastfeeding (large doses may decrease milk production and cause infant sedation); narrow-angle glaucoma (absolute); urinary retention (absolute).
Hypersensitivity to triprolidine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Monoamine oxidase inhibitor (MAOI) therapy (concurrent or within 14 days),Narrow-angle glaucoma,Urinary retention,During or within 14 days of MAOI use
No significant food interactions. Grapefruit juice may theoretically inhibit CYP2D6 metabolism, but clinical relevance is minimal. Avoid alcohol due to additive CNS depression.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours.
First trimester: No increased risk of major congenital anomalies based on large cohort studies, though a weak association with oral clefts has been reported (RR ~1.3-1.5). Second trimester: No known risk. Third trimester: Near term, high doses may cause oxytocin-like effects; once-daily antihistamine effect with minimal fetal risk. Avoid use during late third trimester due to potential for uterine hyperstimulation.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration.
Breastfeeding safety: Compatible, but caution advised due to potential for sedation and irritability in the infant. M/P ratio: Not clinically established; oral bioavailability is low but infant exposure is minimal at typical maternal doses. Avoid use in nursing mothers if alternative antihistamines with better safety profiles are available.
Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3.5. Triprolidine is present in milk. Potential for irritability, sleep disturbance in infants; may reduce milk supply. Use with caution; alternative preferred. Discontinue breastfeeding or drug based on necessity.
No specific dosing adjustments recommended based on pregnancy-induced pharmacokinetic changes. However, due to increased volume of distribution and altered hepatic metabolism in pregnancy, some clinicians may use lower starting doses for efficacy. Monitor for excessive sedation and adjust accordingly.
No specific dose adjustment recommended for pregnancy; however, increased plasma volume may reduce drug concentrations. Use lowest effective dose due to limited safety data. Avoid in hypertension or preeclampsia.
Diphenhydramine is a first-generation antihistamine with strong anticholinergic effects; avoid in elderly due to increased risk of confusion, falls, and urinary retention. Rapid IV administration can cause hypotension and arrhythmias; give slow IV push. Use with caution in patients with glaucoma, prostate hypertrophy, or asthma. Onset of sedation within 30-60 minutes; useful for acute dystonias (e.g., from antipsychotics) at 25-50 mg IM/IV. Not recommended for children <2 years due to risk of respiratory depression.
Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma.
Do not drive or operate heavy machinery until you know how this drug affects you, as it causes drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and fall risk.,Dry mouth, blurred vision, and constipation are common; drink water and use sugar-free gum for dry mouth.,If you have difficulty urinating or eye pain, stop the medication and seek medical help.,Do not exceed recommended dose; overdose can cause seizures, hallucinations, or serious heart problems.,Take with food if stomach upset occurs, but avoid grapefruit juice as it may affect drug metabolism.
Do not take with other cold or allergy medications containing decongestants or antihistamines.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not crush or chew extended-release tablets; swallow whole.,Monitor for increased blood pressure or heart rate; discontinue if palpitations occur.,May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you.
"Diphenhydramine, a first-generation antihistamine with significant central nervous system (CNS) depressant effects, and clonazepam, a benzodiazepine that enhances GABA-A receptor activity, produce additive CNS depression when co-administered. This synergistic effect increases the risk of excessive sedation, psychomotor impairment, respiratory depression, and potential for falls, especially in elderly patients. Clinically, patients may experience profound drowsiness, confusion, ataxia, and impaired cognitive and motor function, which can lead to accidents or worsen sleep-disordered breathing."
"Concurrent use of diphenhydramine and butalbital results in additive central nervous system (CNS) depression due to their overlapping sedative-hypnotic properties. Diphenhydramine, a first-generation antihistamine, antagonizes histamine H1 receptors and crosses the blood-brain barrier, while butalbital, a barbiturate, enhances GABA-A receptor activity. This synergism can lead to excessive sedation, impaired cognitive and motor function, respiratory depression, and increased risk of accidental injury or overdose, particularly in elderly patients or those with hepatic impairment."
"Cevimeline, a muscarinic agonist used for xerostomia, can inhibit the metabolism of diphenhydramine by competitively blocking cytochrome P450 (CYP) 2D6 and 3A4 enzymes. This results in reduced clearance of diphenhydramine, leading to elevated plasma concentrations and increased risk of anticholinergic side effects such as sedation, confusion, dry mouth, blurred vision, and urinary retention. Clinically, patients may experience enhanced and prolonged central nervous system depression and anticholinergic toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Diphenhydramine vs ACTIFED, answered by our medical review team.
Diphenhydramine is a Antihistamine that works by Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.. ACTIFED is a Decongestant/Antihistamine Combination that works by ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Diphenhydramine and ACTIFED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Diphenhydramine is: 25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).. The standard adult dose of ACTIFED is: 1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Diphenhydramine and ACTIFED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Diphenhydramine is classified as Category C. First trimester: No increased risk of major congenital anomalies based on large cohort studies, though a weak association with oral clefts has been reported (RR ~1.3-1.5). Second t. ACTIFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.